Quantcast

Experts to Discuss the Changing EMA and Reform of Pharma Legislation at the EuroMeeting 2014

March 18, 2014

The 26th annual EuroMeeting, coming to Austria’s capital from 25-27 March, will feature more than 100 sessions in 16 parallel themes and the chance to hear from 300+ expert speakers, including representatives from the European Medicines Agency (EMA), the European Commission and regulatory agencies from around the world.

BASEL, SWITZERLAND (PRWEB) March 18, 2014

In less than one week’s time more than 2,500 professionals from around the world will gather in Vienna at DIA’s largest conference in Europe – the EuroMeeting 2014.

The 26th annual EuroMeeting, coming to Austria’s capital from 25-27 March, will feature more than 100 sessions in 16 parallel themes and the chance to hear from 300+ expert speakers, including representatives from the European Medicines Agency (EMA), the European Commission and regulatory agencies from around the world.

A key discussion point will be The Changing Face of the EMA – Inside and Out: An Overview of the New Structure and Expectations from the Changes. Chaired by Melanie Carr, Head of the Small and Medium-sized Enterprise Office in the Stakeholders and Communication Division at the European Medicines Agency, this session will shed light on the changes underway to the EMA’s operating processes and what it will mean for applicant companies.

The Case for and Against a Reform of the Pharmaceutical Legislation will be another popular session, chaired by David Jefferys, Senior Vice President of Esai Medical Research, UK. Speakers will give the latest updates on the Escher Project, views on conditional authorization, and reveal the challenges of safety referrals.

Attendees can maximize their learning prior to the EuroMeeting 2014 by registering for one of 13 pre-conference tutorials giving the latest information in pharmaceutical law, pharmacovigilance legislation, signal management systems, safety data, biosimilars, medical devices, paediatrics, Health Technology Assessment, and much more.

Plus, participants can find out about the latest innovations in their field by touring the exhibition hall featuring 170 companies, and view the latest research on display through student and professional posters.

For those who can’t get out of the office for the full three days of the EuroMeeting 2014, DIA is offering professionals the option to just attend the day with the sessions they are most interested in with a one-day rate. To register for the one-day rate email diaeurope(at)diaeurope(dot)org with your details (there is no online registration available for this special rate).

To register to attend the full three-day meeting and preconference tutorials, or for more information, visit the EuroMeeting 2014 website at http://www.diahome.org/EM2014.

ABOUT DIA

DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments.

The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients.

DIA is an independent, nonprofit organization headquartered in Washington, D.C., USA with regional offices covering North and South America (Horsham, Pennsylvania, USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing).

For more information, visit http://www.diahome.org or call DIA’s Global Headquarters at 1-202-601-8902.

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/03/prweb11680597.htm


Source: prweb



comments powered by Disqus